Manhattan/Nordic Head Lice Therapy Will Be Reviewed As Device
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies amend February deal that created a joint venture to develop and market Hedrin.
You may also be interested in...
Manhattan Pharmaceuticals To Focus On Dermatology After Obesity Candidate Fails
Firm will discontinue development of oral oleoyl-estrone for obesity after it failed to show a significant difference over placebo in Phase IIa studies.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.